Active Ingredient: Aflibercept
Strength: 2 mg (0.05 mL)
Dosage Form: Injection (intravitreal)
Mechanism of Action: VEGF-A and PlGF inhibitors
First Approval: US (18 Nov 2011), EU (27 Nov 2012)
Revenue1
EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…
